| Identification | Back Directory | [Name]
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-Methyl-1H-iMidazol-1-yl)acetaMido)-2-(o-tolyl)acetaMide | [CAS]
1355326-35-0 | [Synonyms]
CS-720
IDH C35
IDH-C35
AGI5198
AGI 5196
AGI-5198, >=98%
IDH-C35 /IDHC35
AGI-5198 (IDH-C35)
IDH-C35;AGI5198;AGI 5196
AGI5198; AGI-5198; AGI 5198; IDHC35; IDH-C35; IDH C35.
N-Cycohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-Methyl-1H-iMidazol-1-yl)acetaMido)-2-(o-tolyl)acetaMide
N-cyclohexyl-2-(3-fluoro-N-[2-(2-methylimidazol-1-yl)acetyl]anilino)-2-(2-methylphenyl)acetamide
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-Methyl-1H-iMidazol-1-yl)acetaMido)-2-(o-tolyl)acetaMide USP/EP/BP
N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide
1H-Imidazole-1-acetamide, N-[2-(cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-
N-CYCLOHEXYL-2-(N-(3-FLUOROPHENYL)-2-(2-METHYL-1H-IMIDAZOL-1-YL)ACETAMIDO)-2-(O-TOLYL)ACETAMIDE;AGI5198;IDH-C35 /IDHC35
N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide AGI 5198 | [EINECS(EC#)]
806-071-1 | [Molecular Formula]
C27H31FN4O2 | [MDL Number]
MFCD24848688 | [MOL File]
1355326-35-0.mol | [Molecular Weight]
462.56 |
| Chemical Properties | Back Directory | [Boiling point ]
707.6±60.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble3mg/mL, clear | [form ]
powder | [pka]
14.02±0.20(Predicted) | [color ]
white to beige | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | [InChIKey]
FNYGWXSATBUBER-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Description]
AGI-5198 (135526-35-0) is a potent (IC50?= 70 nM) inhibitor of mutant isocitrate dehydrogenase 1(IDH1).1? It is selective for the R132H-IDH1 mutant and does not affect wild type cells.2? This mutation results in loss-of-function for oxidative decarboxylation of isocitrate and gain-of-function for production of the oncometabolite R-2-hydroxyglutarate (R-2HG) from alpha-ketoglutarate (2-OG). | [Uses]
AGI5198 inhibits mutant IDH1 (isocitrate dehydrogenase 1) in cancer cells which delays growth and promotes differentiation of the glioma cells. | [Biochem/physiol Actions]
In human chondrosarcoma cell line JJ012, AGI-5198 promotes apoptosis and G2/M cell cycle arrest. It also prevents the generation of colony in chondrosarcoma cell lines. AGI-5198 hinders the multiplication of cell and induces demethylation of H3K9me3 and H3K27me3. | [target]
R132H-IDH1 | [storage]
Store at -20°C | [References]
1) Popovici-Muller?et al. (2012),?Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG In Vivo; ACS Med. Chem. Lett.,?3?850
2) Rohle?et al. (2013),?An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells; Science,?340?626 |
|
|